BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15310757)

  • 1. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.
    Tanimoto Y; Yokozeki M; Hiura K; Matsumoto K; Nakanishi H; Matsumoto T; Marie PJ; Moriyama K
    J Biol Chem; 2004 Oct; 279(44):45926-34. PubMed ID: 15310757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts.
    Suzuki H; Suda N; Shiga M; Kobayashi Y; Nakamura M; Iseki S; Moriyama K
    J Cell Physiol; 2012 Sep; 227(9):3267-77. PubMed ID: 22105374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts.
    Mansukhani A; Bellosta P; Sahni M; Basilico C
    J Cell Biol; 2000 Jun; 149(6):1297-308. PubMed ID: 10851026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model.
    Morita J; Nakamura M; Kobayashi Y; Deng CX; Funato N; Moriyama K
    Dev Dyn; 2014 Apr; 243(4):560-7. PubMed ID: 24259495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of the Apert canonical S252W FGFR2 mutation in a patient without severe syndactyly.
    Passos-Bueno MR; Richieri-Costa A; Sertié AL; Kneppers A
    J Med Genet; 1998 Aug; 35(8):677-9. PubMed ID: 9719378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis.
    Lemonnier J; Haÿ E; Delannoy P; Lomri A; Modrowski D; Caverzasio J; Marie PJ
    J Bone Miner Res; 2001 May; 16(5):832-45. PubMed ID: 11341328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis.
    Yokota M; Kobayashi Y; Morita J; Suzuki H; Hashimoto Y; Sasaki Y; Akiyoshi K; Moriyama K
    PLoS One; 2014; 9(7):e101693. PubMed ID: 25003957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model.
    Yang F; Wang Y; Zhang Z; Hsu B; Jabs EW; Elisseeff JH
    Bone; 2008 Jul; 43(1):55-63. PubMed ID: 18407821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR2 mutation in a patient with Apert syndrome associated with humeroradial synostosis.
    Kanauchi Y; Muragaki Y; Ogino T; Takahara M; Tsuchida H; Ishigaki D
    Congenit Anom (Kyoto); 2003 Dec; 43(4):302-5. PubMed ID: 15041782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P253R fibroblast growth factor receptor-2 mutation induces RUNX2 transcript variants and calvarial osteoblast differentiation.
    Baroni T; Carinci P; Lilli C; Bellucci C; Aisa MC; Scapoli L; Volinia S; Carinci F; Pezzetti F; Calvitti M; Farina A; Conte C; Bodo M
    J Cell Physiol; 2005 Feb; 202(2):524-35. PubMed ID: 15389579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
    Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
    Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrantly activated Wnt/β-catenin pathway co-receptors LRP5 and LRP6 regulate osteoblast differentiation in the developing coronal sutures of an Apert syndrome (Fgfr2
    Min Swe NM; Kobayashi Y; Kamimoto H; Moriyama K
    Dev Dyn; 2021 Mar; 250(3):465-476. PubMed ID: 32822074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dura in the pathogenesis of syndromic craniosynostosis: fibroblast growth factor receptor 2 mutations in dural cells promote osteogenic proliferation and differentiation of osteoblasts.
    Ang BU; Spivak RM; Nah HD; Kirschner RE
    J Craniofac Surg; 2010 Mar; 21(2):462-7. PubMed ID: 20489451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses.
    Passos-Bueno MR; Sertié AL; Richieri-Costa A; Alonso LG; Zatz M; Alonso N; Brunoni D; Ribeiro SF
    Am J Med Genet; 1998 Jul; 78(3):237-41. PubMed ID: 9677057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosome-mediated small interfering RNA delivery inhibits aberrant osteoblast differentiation in Apert syndrome model mice.
    Myo AC; Kobayashi Y; Niki Y; Kamimoto H; Moriyama K
    Arch Oral Biol; 2023 Sep; 153():105753. PubMed ID: 37348363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation.
    Lemonnier J; Delannoy P; Hott M; Lomri A; Modrowski D; Marie PJ
    Exp Cell Res; 2000 Apr; 256(1):158-67. PubMed ID: 10739663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.
    Yu K; Herr AB; Waksman G; Ornitz DM
    Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14536-41. PubMed ID: 11121055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse.
    Wang Y; Xiao R; Yang F; Karim BO; Iacovelli AJ; Cai J; Lerner CP; Richtsmeier JT; Leszl JM; Hill CA; Yu K; Ornitz DM; Elisseeff J; Huso DL; Jabs EW
    Development; 2005 Aug; 132(15):3537-48. PubMed ID: 15975938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excessive osteoclast activation by osteoblast paracrine factor RANKL is a major cause of the abnormal long bone phenotype in Apert syndrome model mice.
    Shin HR; Kim BS; Kim HJ; Yoon H; Kim WJ; Choi JY; Ryoo HM
    J Cell Physiol; 2022 Apr; 237(4):2155-2168. PubMed ID: 35048384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of protein kinase Calpha, interleukin-1alpha, and RhoA guanosine 5'-triphosphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 receptor Apert mutation: identification by analysis of complementary DNA microarray.
    Lomri A; Lemonnier J; Delannoy P; Marie PJ
    J Bone Miner Res; 2001 Apr; 16(4):705-12. PubMed ID: 11315998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.